top of page

Pipeline

Scroll to learn more

KeifeRx is building upon its extensive clinical experience in neurodegenerative diseases to advance a second generation of orally delivered small molecules that demonstrate high blood-brain-barrier penetration, selective kinase inhibition, and enhanced clearance of toxic protein buildup associated with neurodegenerative disease.  Additionally, selective inhibition of kinases related to mast cell-mediated inflammatory conditions has the potential to reduce symptoms for patients suffering from immune conditions. 

Nilotinib

Alzheimer's Disease

Target(s) : c-ABL, c-KIT, FYN

Discovery

Pre-clinical

IND-Enabling

Ph 1

Ph 2

Parkinson's Disease & Dementia

KFRX04

c-ABL, DDR-1

Target(s) : c-KIT, PIKFYVE

KFRX05

Amyotrophic lateral sclerosis (ALS)

Mast Cell Activated Syndrome (MCAS)

Urticaria

Target(s) : c-KIT (mutants), LRRK2

Parkinson's Disease Dementia (PDD)

KFRX06

Parkinson's disease (LRRK2 mutant)

Target(s) : c-KIT (mutants)

Frontotemporal dementia

KFRX06

c-KIT (mutants)

KeifeRx Pipeline vectors.png

Frontotemporal Dementia

KeifeRx Pipeline vectors.png

Parkinson's Disease (LRRK2 Mutant)

KFRX05

c-KIT (mutants), LRRK2

KeifeRx Pipeline vectors.png

Parkinson's Disease Dementia

KeifeRx Pipeline vectors.png

Mast Cell Activated Syndrome

KeifeRx Pipeline vectors.png

Urticaria

KFRX04

c-KIT, PIKFYVE

Amyotrophic Lateral Sclerosis

KeifeRx Pipeline vectors.png

Amyotrophic Lateral Sclerosis

KeifeRx Pipeline vectors.png

c-ABL, c-KIT, FYN

KFRX03

Alzheimer's Disease

c-ABL, DDR-1

KeifeRx Pipeline vectors.png

Parkinson's Disease Dementia

Nilotinib

Candidate

Target(s)

Discovery

Pre-clinical

IND-Enabling

Ph 1

Ph 2

KFRX03

bottom of page